JAZZ Stock — Price, Charts & Analysis

Jazz Pharmaceuticals plc (JAZZ) has a trailing P/E of 16.92x and a forward P/E of 9.58x. This places JAZZ in a moderate earnings multiple territory based on the valuation data currently available on Worldtickers.

JAZZ trades with 16.92x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether JAZZ looks overvalued or undervalued.

JAZZ's P/E of 16.92x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

JAZZ's trailing EPS is $14.60 and forward EPS is $25.77.

EPS, or earnings per share, shows how much profit Jazz Pharmaceuticals plc generated for each share. JAZZ's trailing EPS is $14.60, and investors usually prefer EPS that is positive and growing over time.

Jazz Pharmaceuticals plc has a market cap of $16.03B, making JAZZ a large-cap stock based on the current market value shown on Worldtickers.

JAZZ's latest stock price on Worldtickers is $246.99. The latest move is -$5.17 or -2.05%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

JAZZ's quote includes a latest price of $246.99. The market open is $249.60. Previous close is $252.16. The intraday range is $245.76 to $254.93.

JAZZ is down in the latest quote, with a move of -$5.17 or -2.05%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

JAZZ generated $4.60B in trailing revenue. Revenue growth is 15.50%, which helps show whether demand is expanding or slowing.

JAZZ's revenue growth is 15.50%, which is a strong demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, JAZZ shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is $940.75M.

Gross margin is 91.35%. Margins show how efficiently Jazz Pharmaceuticals plc turns revenue into profit.

Jazz Pharmaceuticals plc carries $4.41B and holds $2.20B in cash.

JAZZ holds $2.20B on its balance sheet.

JAZZ's book value per share is $74.10.

Institutions hold 103.04% of JAZZ shares. Insiders hold 2.99% of shares. Ownership mix helps investors understand how much of Jazz Pharmaceuticals plc is held by professional investors and company insiders.

JAZZ has 64.91M shares outstanding. Float shares are 62.94M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for JAZZ, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for JAZZ is $25.77. Revenue growth is 15.50%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

JAZZ's trailing EPS is $14.60. Forward EPS is $25.77. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

JAZZ is in the Healthcare sector. Its earnings multiple is 16.92x. Its latest displayed growth metric is 15.50%. Compare these figures with sector peers before deciding whether Jazz Pharmaceuticals plc is stronger or weaker than average.

JAZZ trades at $246.99. The stock trades at 16.92x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Jazz Pharmaceuticals plc's fundamentals.

JAZZ risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.36, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

JAZZ should be compared with companies in Biotechnology. Its earnings multiple is 16.92x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Jazz Pharmaceuticals plc (JAZZ) operates in Healthcare, specifically Biotechnology. Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblast

JAZZ trades on NasdaqGS. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

JAZZ stock is priced in USD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Jazz Pharmaceuticals plc's official website listed on Worldtickers is investor.jazzpharma.com/phoenix.zhtml?c=210227&p=irol-irhome. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Jazz Pharmaceuticals plc employs about 2.89K people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Jazz Pharmaceuticals plc is headquartered in Dublin, Ireland. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

JAZZ is in the Healthcare sector and the Biotechnology industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

JAZZ has traded between $118.19 and $265.05 over the past 52 weeks. At $246.99, it is 6.81% below the high and 108.98% above the low. The 52-week range helps gauge long-term price momentum.

JAZZ is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is $244.23 and its 200-day moving average is $199.45.

JAZZ's RSI is 46.91. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

JAZZ's latest RSI reading is 46.91, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for JAZZ is near $240.63. Key resistance is near $265.05. Breaks above resistance or below support can change the short-term technical setup.

JAZZ's nearest reported support level is $240.63. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

JAZZ's nearest reported resistance level is $265.05. A breakout above resistance can improve momentum, especially when volume confirms the move.

JAZZ trades about 828.83K shares daily on average. The latest displayed volume is 183.13K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

JAZZ's MACD is -1.30, which is a negative momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

JAZZ is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 46.91 (neutral). MACD is bearish. Nearest support is around $240.63. Resistance is around $265.05. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is $253.31 (-2.50% from price). MA50 is $244.23 (1.13% from price). MA200 is $199.45 (23.83% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. JAZZ's MA20 is $253.31. MA50 is $244.23. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

JAZZ's pivot is near $253.45. Support is near $240.63. Resistance is near $265.05. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for JAZZ is near $233.24. The next upper resistance zone is near $255.20. These levels help define risk and possible follow-through zones after a breakout or breakdown.

JAZZ's Bollinger range is roughly $243.70 to $262.92. Band width is near 7.59%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

JAZZ's ATR-based typical daily range is about 2.93%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 183.13K shares. Average volume is about 828.83K shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

JAZZ's all-time high shown on Worldtickers is $265.05. Its all-time low is $0.52. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

JAZZ has a beta of 0.36, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.